Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction of the TEAD Co-activator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.
Gemma C, Lai CF, Singh AK, Belfiore A, Portman N, Milioli HZ, Periyasamy M, Raafat S, Nicholls AJ, Davies CM, Patel NR, Simmons GM, Fan H, Nguyen VTM, Magnani L, Rakha E, Martin LA, Lim E, Coombes RC, Pruneri G, Buluwela L, Ali S. Gemma C, et al. Among authors: buluwela l. Cancer Res. 2024 Oct 2:10.1158/0008-5472.CAN-24-0013. doi: 10.1158/0008-5472.CAN-24-0013. Online ahead of print. Cancer Res. 2024. PMID: 39356622 Free PMC article.
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells.
Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M, Photiou A, Spivey AC, Ortlund EA, Whitby RJ, Carroll JS, Coombes RC, Buluwela L, Ali S. Thiruchelvam PT, et al. Among authors: buluwela l. Breast Cancer Res Treat. 2011 Jun;127(2):385-96. doi: 10.1007/s10549-010-0994-9. Epub 2010 Jul 6. Breast Cancer Res Treat. 2011. PMID: 20607599
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L. Tolhurst RS, et al. Among authors: buluwela l. Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22. Breast Cancer Res Treat. 2011. PMID: 20730598
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.
Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, Remenyi J, Smith S, Gomm JJ, Magnani L, Győrffy B, Jones LJ, Fuller-Pace F, Shousha S, Buluwela L, Rakha EA, Ellis IO, Coombes RC, Ali S. Patel H, et al. Among authors: buluwela l. Clin Cancer Res. 2016 Dec 1;22(23):5929-5938. doi: 10.1158/1078-0432.CCR-15-1104. Epub 2016 Jun 14. Clin Cancer Res. 2016. PMID: 27301701 Free PMC article.
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM. Alao JP, et al. Among authors: buluwela l. Clin Cancer Res. 2004 Dec 1;10(23):8094-104. doi: 10.1158/1078-0432.CCR-04-1023. Clin Cancer Res. 2004. PMID: 15585645
APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.
Periyasamy M, Patel H, Lai CF, Nguyen VTM, Nevedomskaya E, Harrod A, Russell R, Remenyi J, Ochocka AM, Thomas RS, Fuller-Pace F, Győrffy B, Caldas C, Navaratnam N, Carroll JS, Zwart W, Coombes RC, Magnani L, Buluwela L, Ali S. Periyasamy M, et al. Among authors: buluwela l. Cell Rep. 2015 Oct 6;13(1):108-121. doi: 10.1016/j.celrep.2015.08.066. Epub 2015 Sep 24. Cell Rep. 2015. PMID: 26411678 Free PMC article.
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, Ali S, Buluwela L, Diez-Rodriguez M, Caldas C, Green AR, Ellis IO, Rakha EA. Aleskandarany MA, et al. Among authors: buluwela l. Breast Cancer Res Treat. 2016 Sep;159(2):215-27. doi: 10.1007/s10549-016-3934-5. Epub 2016 Aug 11. Breast Cancer Res Treat. 2016. PMID: 27514395 Free article.
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes RC, Ali S. Patel H, et al. Among authors: buluwela l. Mol Cancer Ther. 2018 Jun;17(6):1156-1166. doi: 10.1158/1535-7163.MCT-16-0847. Epub 2018 Mar 15. Mol Cancer Ther. 2018. PMID: 29545334 Free PMC article.
Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells.
Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, Kyle FJ, Thomas RS, Launchbury R, Hua H, Callaghan HB, Carroll JS, Charles Coombes R, Zwart W, Buluwela L, Ali S. Lai CF, et al. Among authors: buluwela l. Nucleic Acids Res. 2013 Dec;41(22):10228-40. doi: 10.1093/nar/gkt827. Epub 2013 Sep 17. Nucleic Acids Res. 2013. PMID: 24049078 Free PMC article.
89 results